CommercialCoverageMedium impact
08.00.49f, Dofetilide (Tikosyn®) Use in the Inpatient Setting
Independence Blue Cross·Pharmacy, Cardiology, Critical Care +1 more·Pharmacy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.49f regarding Dofetilide (Tikosyn®) use in the inpatient setting was reissued effective 03/05/2025. Without access to the full policy text content, the specific billing, coverage, or documentation changes cannot be determined. The medical billing team must obtain and review the complete policy document to identify affected codes, prior authorization requirements, and necessary workflow updates.
Action Required
By 03/05/2025: Billing team and pharmacy staff must obtain the complete policy text from the source URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-49f). Review the full policy for: (1) specific HCPCS J-codes or billing codes for Dofetilide administration, (2) prior authorization requirements for inpatient use, (3) documentation requirements for prescribers and inpatient facilities, and (4) coverage limitations. Update billing system rules, prior authorization workflows, and provider ordering guidelines accordingly. Communicate changes to all prescribing physicians and inpatient departments. Failure to implement required prior authorizations or follow coverage guidelines may result in claim denials.